RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2011 /PRNewswire/ —
Talecris Biotherapeutics Holdings Corp. (Nasdaq:
TLCR) announced today that NASDAQ has removed TLCR from the
NASDAQ Biotechnology Index(R) (Nasdaq: NBI) in anticipation of the
company’s pending acquisition by Grifols S.A. The change takes
effect Feb. 15 prior to the market’s opening.
This customary NASDAQ policy is intended to provide stockholders
with advance notice of a company’s anticipated merger or
acquisition in order to allow them time to sell their position. If
the acquisition is not completed, NASDAQ plans to reinstate
Talecris in the Biotechnology Index during the following
semi-annual re-ranking of securities. Talecris was initially added
to the NASDAQ Biotechnology Index on May 24, 2010.
The Biotechnology Index is designed to track the performance of
a set of NASDAQ-listed securities that are classified as either
biotechnology or pharmaceutical according to the Industry
Classification Benchmark (ICB). The NASDAQ Biotechnology Index is
re-ranked semi-annually in May and November.
About Talecris Biotherapeutics: Inspiration. Dedication.
Talecris Biotherapeutics is a global biotherapeutic and
biotechnology company that discovers, develops and produces
critical care treatments for people with life-threatening disorders
in a variety of therapeutic areas including immunology,
pulmonology, neurology and hemostasis. For more information, please